Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1998 1
2000 3
2001 1
2002 4
2003 5
2004 9
2005 8
2006 5
2007 7
2008 1
2009 1
2010 2
2011 4
2012 4
2013 1
2014 5
2015 3
2016 1
2017 1
2020 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

61 results

Results by year

Filters applied: . Clear all
Page 1
A clinical and scientific overview of tositumomab and iodine I 131 tositumomab.
Zelenetz AD. Zelenetz AD. Semin Oncol. 2003 Apr;30(2 Suppl 4):22-30. doi: 10.1053/sonc.2003.23803. Semin Oncol. 2003. PMID: 12728404 Review.
The majority of patients with non-Hodgkin's lymphoma (NHL) who respond to conventional chemotherapy will relapse and eventually become refractory to chemotherapy. Each subsequent remission is typically of similar or shorter duration than the last. Recent deve …
The majority of patients with non-Hodgkin's lymphoma (NHL) who respond to conventional chemotherapy will relapse and eventuall …
Radioimmunotherapy for B-cell non-hodgkin lymphomas.
Tomblyn M. Tomblyn M. Cancer Control. 2012 Jul;19(3):196-203. doi: 10.1177/107327481201900304. Cancer Control. 2012. PMID: 22710895 Free article. Review.
BACKGROUND: Radioimmunotherapy (RIT) is a safe and effective therapeutic option for patients with indolent B-cell non-Hodgkin lymphomas (NHL), in both up-front and relapsed/refractory settings. ...The potential clinical applications of RI …
BACKGROUND: Radioimmunotherapy (RIT) is a safe and effective therapeutic option for patients with indolent B-cell non-H …
Radioimmunotherapy for non-Hodgkin's lymphoma.
Emmanouilides C. Emmanouilides C. Semin Oncol. 2003 Aug;30(4):531-44. doi: 10.1016/s0093-7754(03)00237-9. Semin Oncol. 2003. PMID: 12939722 Review.
Radioimmunotherapy (RIT) treatment for lymphoma is a novel targeted therapeutic approach. Several years of development of radioimmunotherapeutic compounds came to fruition in February of 2002 when the US Food and Drug Administration (FDA) approved yttrium 90 ((90)Y) …
Radioimmunotherapy (RIT) treatment for lymphoma is a novel targeted therapeutic approach. Several years of development of radi …
Tositumomab and (131)I therapy in non-Hodgkin's lymphoma.
Wahl RL. Wahl RL. J Nucl Med. 2005 Jan;46 Suppl 1:128S-40S. J Nucl Med. 2005. PMID: 15653661 Free article. Review.
Tositumomab and (131)I-tositumomab constitute a relatively new radioimmunotherapeutic regimen for patients with CD20+ follicular non-Hodgkin's lymphoma (NHL). Currently, it is approved for use in patients whose disease has relapsed after chemotherapy and is refactor …
Tositumomab and (131)I-tositumomab constitute a relatively new radioimmunotherapeutic regimen for patients with CD20+ follicular non-Hodgkin …
Radioimmunotherapy in mantle cell lymphoma.
Skarbnik AP, Smith MR. Skarbnik AP, et al. Best Pract Res Clin Haematol. 2012 Jun;25(2):201-10. doi: 10.1016/j.beha.2012.04.004. Epub 2012 May 9. Best Pract Res Clin Haematol. 2012. PMID: 22687456 Free PMC article. Review.
Often termed an aggressive lymphoma in the U.S., but included in indolent lymphoma trials in Europe, MCL is not curable with standard immuno-chemotherapy. There is no single standard initial therapy for this disease. Although standard lymphoma therapies yield …
Often termed an aggressive lymphoma in the U.S., but included in indolent lymphoma trials in Europe, MCL is not curable with s …
Radioimmunotherapy in follicular lymphoma.
Illidge T, Morschhauser F. Illidge T, et al. Best Pract Res Clin Haematol. 2011 Jun;24(2):279-93. doi: 10.1016/j.beha.2011.03.005. Epub 2011 May 12. Best Pract Res Clin Haematol. 2011. PMID: 21658624 Review.
Recent data have demonstrated that fractionated radioimmunotherapy targeting CD22 with (90)Y-epratuzumab tetraxetan achieved a high degree of durable complete responses in relapsed/refractory NHL. ...This chapter reviews the progress that has been made in the …
Recent data have demonstrated that fractionated radioimmunotherapy targeting CD22 with (90)Y-epratuzumab tetraxetan achieved a high d …
Iodine 131 tositumomab in the treatment of non-Hodgkin's lymphoma.
Smith S, Sweetenham JW. Smith S, et al. Future Oncol. 2007 Jun;3(3):255-62. doi: 10.2217/14796694.3.3.255. Future Oncol. 2007. PMID: 17547519 Review.
I131 tositumomab exploits the specificity of monoclonal antibody therapy and the radiosensitivity of non-Hodgkin's lymphoma to exact a combined antitumor effect. It is currently approved in the USA for treatment of relapsed or refractory low-grade (and transf …
I131 tositumomab exploits the specificity of monoclonal antibody therapy and the radiosensitivity of non-Hodgkin's lymphoma to exact …
Iodine-131 tositumomab (Bexxar): radioimmunoconjugate therapy for indolent and transformed B-cell non-Hodgkin's lymphoma.
Friedberg JW, Fisher RI. Friedberg JW, et al. Expert Rev Anticancer Ther. 2004 Feb;4(1):18-26. doi: 10.1586/14737140.4.1.18. Expert Rev Anticancer Ther. 2004. PMID: 14748653 Review.
The iodine-131 tositumomab regimen was approved by the US Food and Drug Administration in June 2003 for the treatment of patients with CD20-positive, follicular non-Hodgkin's lymphoma, both with and without transformation, whose disease is refractory to rituximab (R …
The iodine-131 tositumomab regimen was approved by the US Food and Drug Administration in June 2003 for the treatment of patients with CD20- …
Radioimmunotherapy for B-cell lymphoma: Y90 ibritumomab tiuxetan and I(131) tositumomab.
Davies AJ. Davies AJ. Oncogene. 2007 May 28;26(25):3614-28. doi: 10.1038/sj.onc.1210378. Oncogene. 2007. PMID: 17530015 Review.
Radioimmunotherapy, targeting the CD20 antigen, in B-cell lymphoma has clearly demonstrated efficacy and tolerability over the preceding 15 years. ...Both demonstrate high-response rates and durability of remission in the relapsed/refractory …
Radioimmunotherapy, targeting the CD20 antigen, in B-cell lymphoma has clearly demonstrated efficacy and tolerab …
Radioimmunotherapy of non-Hodgkin's lymphoma: from the 'magic bullets' to 'radioactive magic bullets'.
Chamarthy MR, Williams SC, Moadel RM. Chamarthy MR, et al. Yale J Biol Med. 2011 Dec;84(4):391-407. Yale J Biol Med. 2011. PMID: 22180677 Free PMC article. Review.
Radioimmunotherapy (RIT) of lymphoma with Zevalin and Bexxar was approved by FDA in 2002 and 2003, respectively, for the treatment of relapsed or refractory CD20+ follicular B-cell non-Hodgkins lymphoma. ...There is also growing in …
Radioimmunotherapy (RIT) of lymphoma with Zevalin and Bexxar was approved by FDA in 2002 and 2003, respectively, for the treat …
61 results